Atezolizumab (atezo) therapy for locally advanced/metastatic urinary tract carcinoma (mUTC) in patients (pts) with poor performance status (PS): Analysis of the prospective global SAUL study.

Daniel Castellano,Craig Gedye,Giuseppe Fornarini,André P. Fay,Jens Voortman,Michal Mego,Aristotelis Bamias,Jason F. Lester,Robert Huddart,Michaela Matoušková,Howard Gurney,Begoña Mellado,Michael K. Ong,Filipa Carneiro,Florian Seseke,Laura Milesi,Shahrokh F. Shariat,Simon Fear,Sabine de Ducla,Cora N. Sternberg

Atezolizumab (atezo) therapy for locally advanced/metastatic urinary tract carcinoma (mUTC) in patients (pts) with poor performance status (PS): Analysis of the prospective global SAUL study.

2020

5035Background: Pts with PS > 1 have a poor prognosis and are often excluded from clinical trials. The single-arm SAUL study (NCT02928406) evaluated atezo in a ‘real-world’ population. Overall, saf...

Keywords:

locally advanced
Urinary system
Internal medicine
Poor performance status
Oncology
Medicine
Carcinoma
Atezolizumab
in patient
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations